ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1591752
This article is part of the Research TopicImportance of Quality Assurance in Radiation Oncology Clinical TrialsView all articles
Clinical Study on Bronchial Artery Chemoembolization for Unresectable Non-Small Cell Lung Cancer
Provisionally accepted
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the efficacy and safety of bronchial artery chemoembolization (BACE) for the treatment of inoperable non-small cell lung cancer (NSCLC). Methods: A retrospective review was conducted of 112 patients with NSCLC who received BACE treatment and 120 patients who underwent systemic chemotherapy in our center over the past 10 years. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), quality of life, and adverse events were compared between the two groups. Results: The complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates in the BACE group were 7.14%, 39.29%, 33.04%, and 20.54%, respectively, while those rates in the chemotherapy group were 7.5%, 20.83%, 55.0%, and 16.67%. The ORR in the BACE group was significantly higher than in the chemotherapy group (46.43% vs. 28.33%, P = 0.007). The median PFS was significantly longer in the BACE group (17 months vs. 11 months, P = 0.035) than that of chemotherapy group, as was the median OS (19.5 months vs. 13 months, P = 0.044). The BACE group also showed significantly better results in cough relief (57.0% vs. 41.7%, P = 0.028) and hemoptysis relief (70.3% vs. 47.1%, P = 0.001) compared to the chemotherapy group. The 1-year, 3-year, and 5-year survival rates for the BACE group were 68.0%, 29.1%, and 15.5%, respectively, compared to 49.5%, 15.9%, and 7.5% those of the chemotherapy group, with statistically significant differences (P < 0.05). The BACE group exhibited better tolerability and higher safety, with a lower incidence and severity of adverse events, particularly fatigue, nausea/vomiting, and myelosuppression, which showed statistically significant differences (P < 0.05). Conclusion: BACE treatment for inoperable NSCLC offers better clinical outcomes compared to systemic chemotherapy and is safe and well-tolerated, with no severe adverse events. This approach warrants further prospective randomized controlled trials.
Keywords: Bronchial arterial chemoembolization, chemotherapy, Non-small cell lung cancer, progress free survival, overall survival
Received: 11 Mar 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Zhang and LIU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu-Jin LIU, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.